Granted Patent
B2
US 12,454,549 · App. 18/206,415 · Granted Oct 28, 2025
Treatments for diseases and disorders that involve oxidative stress
Inventors:
Hampar L Karageozian (San Juan Capistrano, CA); Vicken H Karageozian (San Juan Capistrano, CA); John Y Park (Santa Ana, CA)
Assignee:
Jenius Pharma, LLC
C07K5/06026A61K9/0048A61K31/185A61K38/05A61K38/06A61K38/07A61K38/08A61K38/12A61K47/20C07K5/0806C07K5/081C07K5/0815C07K5/0817C07K5/0819C07K5/0821C07K5/1008C07K5/12C07K7/06C07K7/64
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Peptide compounds and their use in treating diseases and disorders that cause, are caused by, or are characterized by cellular oxidative stress.
Claims (5)
1 . An isolated, synthetic hexapeptide compound consisting of Gly-Arg-Gly-Cys-Thr-Pro (SEQ ID NO:6).
2 . A salt of a compound according to claim 1 .
3 . A compound according to claim 2 , wherein the salt is selected from hydrochloride, acetate, and hydrofluoroacetate.
4 . A pharmaceutical preparation comprising a compound according to claim 1 in combination with at least one pharmaceutically acceptable carrier, diluent, solvent or excipient.
5 . A pharmaceutical preparation comprising a compound according to claim 1 for topical applications to skin or mucous membranes.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 17, 2024
From: KARAGEOZIAN, HAMPAR L.; KARAGEOZIAN, VICKEN H.; PARK, JOHN Y.
To: ALLEGRO PHARMACEUTICALS, LLC
Reel/Frame 069615/0628 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 4, 2024
From: KARAGEOZIAN, HAMPAR L.; KARAGEOZIAN, VICKEN H.; PARK, JOHN Y.
To: ALLEGRO PHARMACEUTICALS, LLC
Reel/Frame 069483/0771 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 10, 2024
From: ALLEGRO PHARMACEUTICALS, L.L.C.
To: JENIUS PHARMA, LLC
Reel/Frame 067376/0103 →
Continuity (5)
Provisional Application
63350373
· Jun 8, 2022
Provisional Application
62521984
· Jun 19, 2017
References Cited (78)
US 6022854A
· Shuman
· 2000
[cited by applicant]
US 9018352B2
· Mackel et al.
· 2015
[cited by applicant]
US 9872886B2
· Mackel et al.
· 2018
[cited by applicant]
US 9896480B2
· Mackel et al.
· 2018
[cited by applicant]
US 20060270005A1
· Marliere et al.
· 2006
[cited by applicant]
US 20100311052A1
· Bendtzen et al.
· 2010
[cited by applicant]
US 20160058881A1
· DiMarchi et al.
· 2016
[cited by applicant]
US 20180207227A1
· Karageozian et al.
· 2018
[cited by applicant]
US 20200345805A1
· Karageozian et al.
· 2020
[cited by applicant]
US 20200354402A1
· Park et al.
· 2020
[cited by applicant]
US 20200392181A1
· Park et al.
· 2020
[cited by applicant]
US 20210085749A1
· Karageozian et al.
· 2021
[cited by applicant]
US 20210275624A1
· Karageozian et al.
· 2021
[cited by applicant]
US 20220031800A1
· Karageozian et al.
· 2022
[cited by applicant]
CN 1849132A
· 2006
[cited by applicant]
JP H10146195A
· 1998
[cited by applicant]
JP 2003313119A
· 2003
[cited by applicant]
WO WO9415953A1
· 1994
[cited by applicant]
WO WO9420531A1
· 1994
[cited by applicant]
WO WO9833494A1
· 1998
[cited by applicant]
WO WO0181581A2
· 2001
[cited by applicant]
WO WO2008152508A2
· 2008
[cited by applicant]
WO WO2011005540A1
· 2011
[cited by applicant]
WO WO2011060104A2
· 2011
[cited by applicant]
WO WO2012045719A2
· 2012
[cited by applicant]
WO WO2012154894A2
· 2012
[cited by applicant]
WO WO2016177898A9
· 2016
[cited by applicant]
WO WO2019036382A1
· 2019
[cited by applicant]
WO WO2021021668A1
· 2021
[cited by applicant]
Lijie Men, et al., Further studies on the fragmentation of protonated ions of peptides containing aspartic acid, glutamic acid, cysteine sulfinic acid, and cysteine sulfonic acid; Rapid Communications in Mass Spectromot…
[cited by applicant]
Mitchell et al., “Polyarginine enters cells more efficiently than other polycationic homopolymers,” J. Peptide Res. 56:318-325 (2000) (Year: 2000).
[cited by applicant]
Morjen et al., “PIVL, a snake venom Kunitz-type serine proteaseinhibitor, inhibits invitro and in vivo angiogenesis,” Microvasc. Res. 95:149-156 (2014) (Year: 2014).
[cited by applicant]
Mc Bean, “Sulfur-Containing Amino Acids”, Handbook of neurochemistry and molecular biology 3rd ed., pp. 134-154 (2007) (Year: 2007).
[cited by applicant]
Cysteic Acid, Cas Reg# 498-40-8, accessed Feb. 21, 2022, at URL commonchemistry.cas.org/detail?cas_rn=498-40-8 (2023). (Year: 2023).
[cited by applicant]
Cysteine, Cas Reg# 52-90-4, accessed Feb. 21, 2022, at URL commonchemistry.cas.org/detail?cas_rn=52-90-4 (2023). (Year: 2023).
[cited by applicant]
UniProtKB A0A2G9RE29 (accessed Feb. 22, 2023 at URL uniprot.org/uniprotkb/A0A2G9RE29.txt (Year: 2023).
[cited by applicant]
UniProtKB A0A0R3WUS0 (accessed Feb. 22, 2023 at URL uniprot.org/uniprotkb/A0A0R3WUS0.txt) (Year: 2023).
[cited by applicant]
Lee, T.T. et al. “Light-triggered in vivo Activation of Adhesive Peptides Regulates Cell Adhesion, Inflammation and Vascularization of Biomaterials”. Nature Materials. Mar. 2015, Epub Dec. 15, 2014, vol. 14, No. 3; pp. …
[cited by applicant]
Cleveland Clinic, Cytokine Release Syndrome (CRS), What It Is & Treatment https://, https://my.clevelandclinic.org/health/diseases/22700-cytokine-release-syndrome (Year: 2022).
[cited by applicant]
Suh, et al., “An Angiogenic, Endothelial-Cell-Targeted Polymeric Gene Carrier”. Molecular Therapy. Nov. 2002, vol. 6, No. 5; pp. 664-672.
[cited by applicant]
Kristensen, T et al. “Primary Structure of Human a2-Macroglobulin”. The Journal of Biological Chemistry. Jul. 10, 1984, vol. 259, No. 13; pp. 8313-8317; p. 8315, 1st column, 4th paragraph.
[cited by applicant]
Luke, Matthias et al., “Effects of the protein tyrosine kinase inhibitor genestein and taurine on retinal function in isolated superfused retina”, Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 245, …
[cited by applicant]
Rodak Roksana et al., “Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by taurolidin…
[cited by applicant]
Tsaprailis, G. et al., “Refining the model for selective cleavage at acidic residues in arginine-containing protonated peptides”, International Journal of Mass Spectrometry, vol. 195-196, Jan. 2000, pp. 467-479.
[cited by applicant]
Liu, Yayuan, et al., “Integrin [alpha]v.[beta]3targeting activity study of different retro-inverso sequences of RGD and their potentiality in the designing of tumor targeting peptides”, Amino Acids, vol. 47, No. 12, Jul…
[cited by applicant]
Nishikawa N. et al, “Synthesis and Biological Properties of Partially Modified Retro and Retro-inverso Pseudo Peptides of Arg-Gly-Asp (RGD)”, Biorganic & Medicinal Chemistry Letters, vol. 6, No. 22, Nov. 1996, pp. 2725-…
[cited by applicant]
Wang, Xiaonan et al., “Oxime chemistry-mediated covalent capturing on electrode surface with guanidinium recognition and application for aldolase activity assay,” Sensors and Actuators B: Chemical, vol. 242, Nov. 2016, …
[cited by applicant]
Lavrinienko et al. “MAG: Ilypotlleticai protein HDR62_04865, part;al [bactenum)” Sep. 29, 2020; Retrieved from the internet on Oct. 25, 2023. <URL: https:/www.ncbi.nlm.nih.gov/protein/MBD5397450.1.
[cited by applicant]
Craig et al. “hypothetical protein HYH02_005451 [Chlamydornonas sch!oesseri)” 2021: Retrieved from the internet on Oct. 25, 2023: <URL:https://www.ncbi.nlm.nih.gov/protein/KAG2449294.1.
[cited by applicant]
Prochnik et al. “hypothetical protein VOLCADRAFT_93629 [
[cited by applicant]
Bogen et al. “NCBI Reference Sequence: XP_013892539.1 (Serine/threonine-protein kinase PAK 7 [Monoraphidium neglectum])” Sep. 10, 2015; Retrieved from the internet on Oct. 25, 2023: <URL:https://www.ncbi.nlm.nih.gov/pro…
[cited by applicant]
PCT International Search Report dated Sep. 24, 2018 in related PCT Application No. PCT/US2018/038365.
[cited by applicant]
PCT International Search Report dated Aug. 19, 2022 in related PCT Application No. PCT/US2022/022316.
[cited by applicant]
PCT International Search Report dated Sep. 22, 2011 in related PCT Application No. PCT/US2023/024573.
[cited by applicant]
Extended European Search Report dated May 11, 2021 in related European Application No. 18820070.3.
[cited by applicant]
Office Action Dated Jul. 19, 2022 in corresponding Japanese Patent Application No. 2019-570511.
[cited by applicant]
Office Action Dated Mar. 19, 2024 in corresponding Japanese Patent Application No. 2023-006767.
[cited by applicant]
Extended European Search Report dated Oct. 8, 2024 in related European Application No. 23193070.2.
[cited by applicant]
Lambert, V., et al., “Laser-Induced Choroidal Neovascularization Model to Study Age Related Macular Degeneration in Mice,” Nature Protocols, vol. 8, No. 11, Nov. 2013, pp. 2197-2211.
[cited by applicant]
Feichtinger, R.G., et al., “Mitochondrial dysfunction: a neglected component of skin diseases”, Experimental Dermatology vol. 23, Issue 9, Sep. 2014 (607-614); https://doi.org/10.1111/exd.12484.
[cited by applicant]
Murphy, M. et al., “Mitochondria as a Therapeutic Target for Common Pathologies”, Nature Reviews: Drug Discovery, Dec. 2018;17(12):865-886. doi: 10.1038/nrd.2018.174. Epub Nov. 5, 2018.
[cited by applicant]
Picard, M. et al., “An Energetic View of Stress: Focus on Mitochondria”, Frontiers in Neuroendocrinology 49 (2018) 72-85.
[cited by applicant]
Giulivi, et al., “Mitochondrial Dysfunction in Autism”, Journal of the American Medical Association, 2010;304:2389-2396.
[cited by applicant]
Chauhan et al., “Brain region⋅specific deficit in mitochondrial electron transport chain complexes in children with autism”, Journal of Neurochemistry 2011; 117:209-22.
[cited by applicant]
Tang, et al., “Mitochondrial abnormalities in temporal lobe of autistic brain”, Neurobiology of Disease 2013;54:349-361.
[cited by applicant]
Goh et al., “Mitochondrial Dysfunction as a Neurobiological Subtype of Autism Spectrum Disorder: Evidence from brain imaging”, JAMA Psychiatry Jun. 2014; vol. 71 No. 6, 665-671.
[cited by applicant]
Napoli, et al., “Deficits in bioenergetics and impaired immune response in granulocytes from children with autism”, Pediatrics May 2014; vol. 133 No. 5, 1405-10.
[cited by applicant]
Rose et al, “Oxidative stress induces mitochondrial dysfunction in a subset of autism lymphoblastoid cell lines in a well-matched case control cohort”, PLOS One 2014;9:e85436.
[cited by applicant]
Parikh et al., “A Modern Approach to the Treatment of Mitochondrial Disease”, Current Treatment Options in Neurology. 2009; 11 : 414-430.
[cited by applicant]
Geier, et al., “A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders”, Med Sci Monit 2011; 17(6): PI15-23.
[cited by applicant]